全文获取类型
收费全文 | 45005篇 |
免费 | 2698篇 |
国内免费 | 258篇 |
专业分类
耳鼻咽喉 | 388篇 |
儿科学 | 1294篇 |
妇产科学 | 1201篇 |
基础医学 | 5912篇 |
口腔科学 | 938篇 |
临床医学 | 4493篇 |
内科学 | 9829篇 |
皮肤病学 | 880篇 |
神经病学 | 4791篇 |
特种医学 | 1498篇 |
外科学 | 5907篇 |
综合类 | 175篇 |
一般理论 | 19篇 |
预防医学 | 3350篇 |
眼科学 | 767篇 |
药学 | 2773篇 |
1篇 | |
中国医学 | 85篇 |
肿瘤学 | 3660篇 |
出版年
2024年 | 70篇 |
2023年 | 520篇 |
2022年 | 998篇 |
2021年 | 1803篇 |
2020年 | 1056篇 |
2019年 | 1484篇 |
2018年 | 1698篇 |
2017年 | 1190篇 |
2016年 | 1336篇 |
2015年 | 1542篇 |
2014年 | 2120篇 |
2013年 | 2640篇 |
2012年 | 3913篇 |
2011年 | 3901篇 |
2010年 | 1972篇 |
2009年 | 1841篇 |
2008年 | 3110篇 |
2007年 | 2999篇 |
2006年 | 2701篇 |
2005年 | 2673篇 |
2004年 | 2231篇 |
2003年 | 1995篇 |
2002年 | 1766篇 |
2001年 | 225篇 |
2000年 | 156篇 |
1999年 | 229篇 |
1998年 | 301篇 |
1997年 | 222篇 |
1996年 | 198篇 |
1995年 | 180篇 |
1994年 | 154篇 |
1993年 | 121篇 |
1992年 | 84篇 |
1991年 | 75篇 |
1990年 | 62篇 |
1989年 | 41篇 |
1988年 | 39篇 |
1987年 | 34篇 |
1986年 | 31篇 |
1985年 | 31篇 |
1984年 | 38篇 |
1983年 | 19篇 |
1982年 | 39篇 |
1981年 | 24篇 |
1980年 | 21篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1976年 | 8篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
22.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献23.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
24.
25.
26.
Andrea DiMartini Nancy Day Mary Amanda Dew Lubna Javed Mary Grace Fitzgerald Ashok Jain John J Fung Paulo Fontes 《Liver transplantation》2006,12(5):813-820
For patients who receive a liver transplant (LTX) for alcoholic liver disease (ALD), investigators are focusing beyond survival to determine specific alcohol use outcomes. Studies suggest the use of alcohol ranges from 8 to 22% for the first post-transplant year with cumulative rates reaching 30 to 40% by 5 years following transplantation. Yet while investigators are interested in determining specific rates of alcohol use and predictors of use, only three studies since 1990 have been prospective. In 1998, we began a prospective study of post-LTX alcohol consumption in ALD recipients using multiple repeated measures of alcohol use. After 5 years of follow-up, we found that 22% had used any alcohol by the first year and 42% had a drink by 5 years. By 5 years, 26% drank at a heavier use (binge) pattern and 20% drank in a frequent pattern. In a univariate model, predictors of alcohol use included pre-transplant length of sobriety, a diagnosis of alcohol dependence, a history of other substance use, and prior alcohol rehabilitation. 相似文献
27.
Susan M Domchek Andrea Eisen Kathleen Calzone Jill Stopfer Anne Blackwood Barbara L Weber 《Journal of clinical oncology》2003,21(4):593-601
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families. 相似文献
28.
Andrea R Genazzani Hermann P G Schneider Nick Panay Esme A Nijland 《Gynecological endocrinology》2006,22(7):369-375
OBJECTIVES: To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer. METHODS: Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol. RESULTS: Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media. CONCLUSIONS: This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use. 相似文献
29.
30.